(ZBH) Zimmer Biomet Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98956P1021

Knee, Hip, Trauma, Spine, Robotics

Stock: Health Care Equipment
Age 24.5y
MCap 17,303m
Avg Vol 1.93M (175M USD)
Beta 0.325
Volatility 25.08%

EPS (Earnings per Share)

EPS (Earnings per Share) of ZBH over the last years for every Quarter: "2020-12": 2.11, "2021-03": 1.71, "2021-06": 1.9, "2021-09": 1.81, "2021-12": 1.95, "2022-03": 1.61, "2022-06": 1.82, "2022-09": 1.58, "2022-12": 1.88, "2023-03": 1.89, "2023-06": 1.82, "2023-09": 1.65, "2023-12": 2.2, "2024-03": 1.94, "2024-06": 2.01, "2024-09": 1.74, "2024-12": 2.31, "2025-03": 1.81, "2025-06": 2.07, "2025-09": 1.9,
EPS CAGR: -0.69%
EPS Trend: 43.9%
Last SUE: 0.69
Qual. Beats: 0

Revenue

Revenue of ZBH over the last years for every Quarter: 2020-12: 2085.3, 2021-03: 1601.4, 2021-06: 1763.3, 2021-09: 1685.4, 2021-12: 2037.9, 2022-03: 1663.2, 2022-06: 1781.8, 2022-09: 1669.8, 2022-12: 1825.1, 2023-03: 1831, 2023-06: 1869.6, 2023-09: 1753.6, 2023-12: 1940.1, 2024-03: 1889.2, 2024-06: 1942, 2024-09: 1824.2, 2024-12: 2023.2, 2025-03: 1909.1, 2025-06: 2077.3, 2025-09: 2001.4,
Rev. CAGR: -0.48%
Rev. Trend: 57.9%
Last SUE: -0.89
Qual. Beats: 0

Dividends

Dividend Yield 0.97%
Yield on Cost 5y 0.65%
Yield CAGR 5y 0.00%
Payout Consistency 97.0%
Payout Ratio 11.9%
Risk via 5d forecast
Volatility 25.1%
Value at Risk 5%th 37.1%
Relative Tail Risk -10.13%
Reward TTM
Sharpe Ratio -0.74
Alpha -27.94
CAGR/Max DD -0.28
Character TTM
Hurst Exponent 0.530
Beta 0.325
Beta Downside 0.261
Drawdowns 3y
Max DD 39.20%
Mean DD 21.42%
Median DD 23.69%

Description: ZBH Zimmer Biomet Holdings December 19, 2025

Zimmer Biomet Holdings Inc. (ZBH) is a global medical-technology firm that designs, manufactures and markets a broad portfolio of orthopedic and cranio-maxillofacial products, including knee and hip implants, sports-medicine devices, bone cement, and surgical robotics that aid surgeons in delivering patient-specific solutions.

In FY 2023 the company generated roughly $7.8 billion in revenue, with operating margins around 12 % and a 6 % year-over-year increase in robot-assisted procedure volumes-a key growth engine as hospitals adopt minimally invasive technologies. Core demand drivers include an aging U.S. population, rising prevalence of osteoarthritis, and Medicare’s evolving reimbursement policies that increasingly favor bundled-payment models and value-based care.

For a data-rich, quantitative deep-dive into ZBH’s valuation metrics and scenario analyses, consider reviewing its profile on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income: 805.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.08 > 1.0
NWC/Revenue: 42.84% < 20% (prev 17.02%; Δ 25.82% < -1%)
CFO/TA 0.07 > 3% & CFO 1.69b > Net Income 805.2m
Net Debt (6.82b) to EBITDA (2.38b): 2.87 < 3
Current Ratio: 2.43 > 1.5 & < 3
Outstanding Shares: last quarter (198.8m) vs 12m ago -2.07% < -2%
Gross Margin: 71.44% > 18% (prev 0.72%; Δ 7072 % > 0.5%)
Asset Turnover: 35.44% > 50% (prev 34.97%; Δ 0.47% > 0%)
Interest Coverage Ratio: 4.61 > 6 (EBITDA TTM 2.38b / Interest Expense TTM 282.8m)

Altman Z'' 4.05

A: 0.15 (Total Current Assets 5.83b - Total Current Liabilities 2.40b) / Total Assets 23.49b
B: 0.49 (Retained Earnings 11.52b / Total Assets 23.49b)
C: 0.06 (EBIT TTM 1.30b / Avg Total Assets 22.60b)
D: 1.05 (Book Value of Equity 11.24b / Total Liabilities 10.72b)
Altman-Z'' Score: 4.05 = AA

Beneish M -3.02

DSRI: 1.02 (Receivables 1.60b/1.48b, Revenue 8.01b/7.60b)
GMI: 1.00 (GM 71.44% / 71.78%)
AQI: 0.97 (AQ_t 0.66 / AQ_t-1 0.68)
SGI: 1.05 (Revenue 8.01b / 7.60b)
TATA: -0.04 (NI 805.2m - CFO 1.69b) / TA 23.49b)
Beneish M-Score: -3.02 = AA

ValueRay F-Score (Strict, 0-100) 69.58

1. Piotroski: 8.0pt
2. FCF Yield: 6.64%
3. FCF Margin: 19.99%
4. Debt/Equity: 0.64
5. Debt/Ebitda: 2.87
6. ROIC - WACC: 0.37%
7. RoE: 6.42%
8. Revenue Trend: 57.90%
9. EPS Trend: 43.93%

What is the price of ZBH shares?

As of January 25, 2026, the stock is trading at USD 86.60 with a total of 1,797,447 shares traded.
Over the past week, the price has changed by -0.81%, over one month by -2.91%, over three months by -15.83% and over the past year by -21.22%.

Is ZBH a buy, sell or hold?

Zimmer Biomet Holdings has received a consensus analysts rating of 3.45. Therefor, it is recommend to hold ZBH.
  • Strong Buy: 5
  • Buy: 6
  • Hold: 16
  • Sell: 1
  • Strong Sell: 1

What are the forecasts/targets for the ZBH price?

Issuer Target Up/Down from current
Wallstreet Target Price 102.4 18.2%
Analysts Target Price 102.4 18.2%
ValueRay Target Price 79.8 -7.9%

ZBH Fundamental Data Overview January 19, 2026

P/E Trailing = 21.665
P/E Forward = 10.2669
P/S = 2.16
P/B = 1.3564
P/EG = 0.8925
Revenue TTM = 8.01b USD
EBIT TTM = 1.30b USD
EBITDA TTM = 2.38b USD
Long Term Debt = 7.51b USD (from longTermDebt, last quarter)
Short Term Debt = 600.0m USD (from shortTermDebt, last quarter)
Debt = 8.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.82b USD (from netDebt column, last quarter)
Enterprise Value = 24.12b USD (17.30b + Debt 8.11b - CCE 1.29b)
Interest Coverage Ratio = 4.61 (Ebit TTM 1.30b / Interest Expense TTM 282.8m)
EV/FCF = 15.07x (Enterprise Value 24.12b / FCF TTM 1.60b)
FCF Yield = 6.64% (FCF TTM 1.60b / Enterprise Value 24.12b)
FCF Margin = 19.99% (FCF TTM 1.60b / Revenue TTM 8.01b)
Net Margin = 10.05% (Net Income TTM 805.2m / Revenue TTM 8.01b)
Gross Margin = 71.44% ((Revenue TTM 8.01b - Cost of Revenue TTM 2.29b) / Revenue TTM)
Gross Margin QoQ = 72.05% (prev 71.49%)
Tobins Q-Ratio = 1.03 (Enterprise Value 24.12b / Total Assets 23.49b)
Interest Expense / Debt = 0.93% (Interest Expense 75.4m / Debt 8.11b)
Taxrate = 17.19% (48.0m / 279.2m)
NOPAT = 1.08b (EBIT 1.30b * (1 - 17.19%))
Current Ratio = 2.43 (Total Current Assets 5.83b / Total Current Liabilities 2.40b)
Debt / Equity = 0.64 (Debt 8.11b / totalStockholderEquity, last quarter 12.76b)
Debt / EBITDA = 2.87 (Net Debt 6.82b / EBITDA 2.38b)
Debt / FCF = 4.26 (Net Debt 6.82b / FCF TTM 1.60b)
Total Stockholder Equity = 12.54b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.56% (Net Income 805.2m / Total Assets 23.49b)
RoE = 6.42% (Net Income TTM 805.2m / Total Stockholder Equity 12.54b)
RoCE = 6.51% (EBIT 1.30b / Capital Employed (Equity 12.54b + L.T.Debt 7.51b))
RoIC = 5.46% (NOPAT 1.08b / Invested Capital 19.80b)
WACC = 5.09% (E(17.30b)/V(25.42b) * Re(7.11%) + D(8.11b)/V(25.42b) * Rd(0.93%) * (1-Tc(0.17)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.38%
[DCF Debug] Terminal Value 86.56% ; FCFF base≈1.46b ; Y1≈1.49b ; Y5≈1.65b
Fair Price DCF = 213.6 (EV 49.15b - Net Debt 6.82b = Equity 42.33b / Shares 198.2m; r=5.90% [WACC]; 5y FCF grow 2.13% → 2.90% )
EPS Correlation: 43.93 | EPS CAGR: -0.69% | SUE: 0.69 | # QB: 0
Revenue Correlation: 57.90 | Revenue CAGR: -0.48% | SUE: -0.89 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.92 | Chg30d=-0.003 | Revisions Net=-2 | Analysts=21
EPS next Year (2026-12-31): EPS=8.48 | Chg30d=-0.027 | Revisions Net=-4 | Growth EPS=+3.7% | Growth Revenue=+5.1%

Additional Sources for ZBH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle